SCHEMBL4094412

SCHEMBL4094412

CCN1CCC[C@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080039 1.00
SCHEMBL3950159 1.00
SCHEMBL14155734 0.93 ALDH1A1 (0.45)
SCHEMBL8977472 0.93 ALDH1A1 (0.45)
SCHEMBL6436481 0.93 ALDH1A1 (0.45)
SCHEMBL16941609 0.86
SCHEMBL22208100 0.86
SCHEMBL16978990 0.86
SCHEMBL6629974 0.84 ALDH1A1 (0.49)
SCHEMBL20999795 0.84 ALDH1A1 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630559-B2 Spirocyclic-substituted 6,7-dihydro-pyrano[2,3- d]pyrimidine inhibitors of KRAS G12C mutant MERCK SHARP & DOHME LLC (US) 2026-05-19 US disclosed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 US disclosed
US-12612387-B2 RAS inhibitors and methods of using the same JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2026-04-28 US disclosed
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 US disclosed
EP-4430035-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 Pharma LLC (US) 2024-09-18 EP disclosed
EP-4374858-A2 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-29 EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 CN disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 US disclosed
US-20240124478-A1 SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT MERCK SHARP & DOHME LLC 2024-04-18 US disclosed
US-20070197546-A1 QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM SPA, ITALY 2007-08-23 US disclosed
US-20070197546-A1 QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM SPA, ITALY 2007-08-23 US disclosed
WO-2007025009-A2 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2007-03-01 WO disclosed
US-20070049555-A1 Indenoisoquinolinone analogs and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-03-01 US disclosed
US-20070049555-A1 Indenoisoquinolinone analogs and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-03-01 US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
US-20050107386-A1 Methods of treating diseases and disorders by targeting multiple kinases NARLA RAMA KRISHNA (US) 2005-05-19 US disclosed
US-20040214837-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-10-28 US disclosed
EP-0692470-A1 Process for the preparation of optically active 1-substituted-2-(aminomethyl)pyrrolidine derivatives Degussa Aktiengesellschaft (DE) 1996-01-17 EP disclosed
WO-1994007841-A1 PROCESS FOR REDUCING CARBOXYLIC ACIDS OR CARBOXYLIC ACID DERIVATIVES, AND NOVEL COMPOUNDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1994-04-14 WO disclosed